Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.0142061281337047 -0.0947075208913649 -0.100278551532033 -0.100278551532033
Stock impact report

Impax Labs gets final FDA approval for generic of Novartis' Focalin XR [Seeking Alpha]

IMPAX LABORATORIES (IPXL) 
Last impax laboratories earnings: 3/1 07:00 am Check Earnings Report
Company Research Source: Seeking Alpha
Impax Laboratories (NASDAQ: IPXL ) premarket after saying it received final FDA approval of its Abbreviated New Drug Application for a generic version of Novartis' Focalin XR extended release capsules and has immediately initiated commercialization activities. According to IMS Health, dexmethylphenidate hydrochloride extended-release capsules, 25 and 35 mg, totaled $93M in U.S. brand and generic sales for the 12 months ending in May. Now read: Pfizer: Is It Really That Bad? » Show less Read more
Impact Snapshot
Event Time:
IPXL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for IPXL alerts
Opt-in for
IPXL alerts

from News Quantified
Opt-in for
IPXL alerts

from News Quantified